Head-To-Head Survey: Siga Technologies (NASDAQ:SIGA) & EOM Pharmaceutical (OTCMKTS:IMUC)

Siga Technologies (NASDAQ:SIGA) and EOM Pharmaceutical (OTCMKTS:IMUC) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, earnings, analyst recommendations and valuation.

Institutional & Insider Ownership

55.4% of Siga Technologies shares are owned by institutional investors. 2.0% of Siga Technologies shares are owned by company insiders. Comparatively, 3.3% of EOM Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Siga Technologies and EOM Pharmaceutical”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Siga Technologies	$94.57 million	3.68	$23.28 million	$0.31	15.68
EOM Pharmaceutical	N/A	N/A	-$1.89 million	N/A	N/A

Siga Technologies has higher revenue and earnings than EOM Pharmaceutical.

Risk and Volatility

Siga Technologies has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500. Comparatively, EOM Pharmaceutical has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500.

Profitability

This table compares Siga Technologies and EOM Pharmaceutical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Siga Technologies	24.61%	11.25%	9.98%
EOM Pharmaceutical	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Siga Technologies and EOM Pharmaceutical, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Siga Technologies	0	1	0	0	2.00
EOM Pharmaceutical	0	0	0	0	0.00

Summary

Siga Technologies beats EOM Pharmaceutical on 8 of the 9 factors compared between the two stocks.

About Siga Technologies

SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.

About EOM Pharmaceutical

Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.